N1-Methylpseudouridine: Advancing mRNA Research with Enhanced Translation and Immune Modulation

Introduction

The rapid evolution of mRNA-based technologies has propelled the need for chemically modified nucleosides that optimize translation efficiency, modulate immune responses, and support diverse research applications. Among these, N1-Methylpseudouridine (N1-methyl-pseudouridine modified nucleoside) has emerged as a critical tool for mRNA modification for protein expression, particularly in the context of translation regulation via eIF2α phosphorylation and innate immune response modulation. While prior literature has explored its general benefits for mRNA therapeutics, the mechanistic basis and experimental considerations for its use in advanced cellular and animal models remain less thoroughly detailed. This article aims to fill that gap, drawing explicit connections to recent findings in mitochondrial proteostasis and metabolic regulation, and providing practical guidance for researchers in cancer and neurodegenerative disease model systems.

Mechanistic Insights: N1-Methylpseudouridine and mRNA Translation Enhancement

The incorporation of N1-methyl-pseudouridine into synthetic mRNA sequences has been shown to substantially enhance translation efficiency. At the molecular level, this nucleoside modification suppresses the activation of innate immune sensors (such as Toll-like receptors and RIG-I-like receptors) and diminishes eIF2α phosphorylation-dependent inhibition, which can otherwise lead to ribosome stalling and reduced protein synthesis. By mitigating these inhibitory pathways, N1-Methylpseudouridine increases both ribosome pausing and overall density on mRNA transcripts, facilitating more robust translation and higher protein output.

Comparative studies demonstrate that N1-Methylpseudouridine outperforms other modified nucleosides, such as 5-methylcytidine, in terms of translation capacity and reduction of cytotoxicity across multiple mammalian cell lines (including A549, BJ, C2C12, HeLa, and primary keratinocytes). Notably, when combined with 5-methylcytidine, it further attenuates intracellular innate immune activation, resulting in improved viability and protein expression in sensitive systems.

Reduced Immunogenicity in mRNA: Implications for Therapeutics and Disease Modeling

One of the persistent challenges in developing mRNA therapeutics and disease models is the activation of innate immune responses, which can limit mRNA stability and expression duration. The use of N1-Methylpseudouridine in mRNA constructs significantly diminishes immunogenicity, as evidenced by studies in both cell culture and animal models. For example, in 7-week-old Balb/c mice, mRNA containing N1-Methylpseudouridine delivered via intradermal or intramuscular lipofection produced superior protein expression and lower immunogenicity compared to pseudouridine-containing mRNA. These findings are particularly relevant for cancer research and neurodegenerative disease model development, where chronic or iterative mRNA delivery is often necessary and immune activation can confound experimental results.

Mechanistically, this reduced immunogenicity is attributed to decreased activation of pattern recognition receptors (PRRs) and lower induction of pro-inflammatory cytokines, supporting a more controlled and sustained protein expression profile. Such immune modulation is essential for both basic research and translational applications, enabling repeated dosing and longitudinal studies without the confounding effects of acute inflammation.

Experimental Considerations: Formulation, Solubility, and Storage for N1-Methylpseudouridine

For optimal performance in experimental workflows, researchers must consider the physicochemical properties of N1-Methylpseudouridine. The compound (C₁₀H₁₄N₂O₆, MW 258.23) is a solid that exhibits high solubility in water (≥50 mg/mL with ultrasonic assistance), ethanol (≥20 mg/mL), and DMSO (≥20.65 mg/mL), facilitating its integration into various mRNA synthesis and delivery protocols. It is essential to prepare fresh solutions for each experiment, as long-term storage of aqueous or organic solutions is not recommended. Bulk material should be stored at –20°C, and appropriate cold-chain shipping (blue ice for small molecules, dry ice for modified nucleotides) is necessary to maintain stability.

When incorporating N1-Methylpseudouridine into mRNA, enzymatic in vitro transcription (IVT) systems can efficiently substitute this nucleoside for uridine, provided that reaction conditions are optimized to account for altered base pairing and polymerase processivity. This approach is compatible with both cap analogs and poly(A) tailing strategies, supporting applications ranging from reporter gene assays to large-scale therapeutic mRNA production.

Intersection with Mitochondrial Metabolism: Translational Regulation and Proteostasis

While the primary focus of N1-Methylpseudouridine research has been on its effects in the cytosolic translation machinery, recent discoveries in mitochondrial proteostasis highlight new avenues for integrating nucleoside modifications with metabolic regulation. For instance, the study by Wang et al. (Molecular Cell, 2025) elucidates how the DNAJC co-chaperone TCAIM specifically binds and reduces a-ketoglutarate dehydrogenase (OGDH) protein levels, thereby modulating TCA cycle activity and energy metabolism. This work underscores the importance of post-translational regulation in synchronizing mitochondrial and cytosolic processes, with direct relevance to cell fate decisions in cancer and neurodegenerative contexts.

By leveraging N1-Methylpseudouridine to maximize cytosolic protein expression while minimizing immune perturbation, researchers can more accurately interrogate the effects of exogenous proteins (such as metabolic enzymes, chaperones, or regulatory factors) on mitochondrial function and proteostasis. The synergy between mRNA translation enhancement and metabolic control mechanisms offers a powerful platform for dissecting cellular bioenergetics, signaling, and stress responses in disease-relevant models.

Applications in Cancer and Neurodegenerative Disease Models

Given the centrality of metabolic rewiring and immune evasion in both cancer and neurodegeneration, reliable modulation of protein expression via mRNA is a critical experimental capability. N1-Methylpseudouridine enables precise titration of gene expression levels in vitro and in vivo, supporting advanced functional genomics, CRISPR-based screens, and therapeutic candidate validation.

In cancer research, the ability to transiently express metabolic regulators such as OGDH or its modulators (e.g., TCAIM, as described by Wang et al., 2025) allows for the dissection of metabolic dependencies and signaling networks that underlie tumor growth and therapy resistance. Similarly, in neurodegenerative disease models, where mitochondrial dysfunction and aberrant proteostasis are hallmarks, mRNA constructs modified with N1-Methylpseudouridine can be used to study the impact of disease-associated mutations or to screen for protective factors in primary neuronal cultures or animal models.

Importantly, the reduced immunogenicity profile of N1-methyl-pseudouridine modified nucleoside ensures that observed phenotypes are attributable to the experimental variable of interest, rather than confounding immune responses. This facilitates clearer interpretation of results and enhances reproducibility across laboratories and experimental systems.

Practical Guidance for Research Implementation

To maximize the benefits of N1-Methylpseudouridine in mRNA research, scientists should adhere to the following best practices:

• Ensure complete substitution of uridine with N1-methyl-pseudouridine during in vitro transcription to achieve uniform modification and minimize innate immune activation.
• Optimize mRNA purification protocols to remove double-stranded RNA contaminants, which may independently trigger immune responses.
• Validate protein expression and immune activation profiles in relevant cell types (e.g., primary keratinocytes, cancer cell lines, neuronal cultures) using quantitative assays (e.g., Western blot, ELISA, cytokine profiling).
• When translating findings to animal models, carefully titrate mRNA doses and monitor both protein expression kinetics and systemic immune parameters to establish dose-response relationships.
• Combine N1-Methylpseudouridine with other modifications (e.g., 5-methylcytidine) or delivery strategies (e.g., lipid nanoparticles, electroporation) to further tailor expression and immunogenicity profiles for specific applications.

Conclusion

N1-Methylpseudouridine represents a transformative advancement in the field of mRNA research, offering unparalleled translation enhancement and immune evasion capabilities. Its integration into mRNA constructs enables precise experimental interrogation of protein function, metabolic regulation, and disease mechanisms in both cellular and animal models. The mechanistic insights provided by recent studies, such as the TCAIM–OGDH axis described by Wang et al. (Molecular Cell, 2025), highlight the broader utility of mRNA modification for studying interconnected pathways of translation, metabolism, and proteostasis.

Unlike earlier reviews such as N1-Methylpseudouridine: Mechanisms of mRNA Translation Enhancement, which primarily focused on the molecular mechanisms of translation, this article provides a distinct perspective by explicitly connecting mRNA modification strategies with recent advances in mitochondrial metabolic regulation. By offering detailed experimental guidance and applications in disease models, this piece extends the field’s understanding of how N1-Methylpseudouridine can be leveraged for both basic and translational research in mRNA therapeutics, cancer, and neurodegenerative disease.